Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States.
+ 1 more risk
Excellent balance sheet and overvalued.
Share Price & News
How has Bio-Path Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BPTH's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: BPTH underperformed the US Biotechs industry which returned 3.9% over the past year.
Return vs Market: BPTH underperformed the US Market which returned -8.1% over the past year.
Price Volatility Vs. Market
How volatile is Bio-Path Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall StHere's Why We're Watching Bio-Path Holdings's (NASDAQ:BPTH) Cash Burn Situation
1 month ago | Simply Wall StWhat Type Of Shareholder Owns Bio-Path Holdings, Inc.'s (NASDAQ:BPTH)?
2 months ago | Simply Wall StAnnouncing: Bio-Path Holdings (NASDAQ:BPTH) Stock Increased An Energizing 184% In The Last Year
Is Bio-Path Holdings undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate BPTH's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate BPTH's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: BPTH is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: BPTH is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BPTH's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BPTH is good value based on its PB Ratio (0.9x) compared to the US Biotechs industry average (2.7x).
How is Bio-Path Holdings forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if BPTH's forecast earnings growth is above the savings rate (1.7%).
Earnings vs Market: Insufficient data to determine if BPTH's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if BPTH's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if BPTH's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BPTH's Return on Equity is forecast to be high in 3 years time
How has Bio-Path Holdings performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BPTH is currently unprofitable.
Growing Profit Margin: BPTH is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BPTH is unprofitable, and losses have increased over the past 5 years at a rate of -12.1% per year.
Accelerating Growth: Unable to compare BPTH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BPTH is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22%).
Return on Equity
High ROE: BPTH has a negative Return on Equity (-40.78%), as it is currently unprofitable.
How is Bio-Path Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: BPTH's short term assets ($22.0M) exceed its short term liabilities ($1.2M).
Long Term Liabilities: BPTH's short term assets ($22.0M) exceed its long term liabilities ($330.0K).
Debt to Equity History and Analysis
Debt Level: BPTH is debt free.
Reducing Debt: BPTH has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BPTH has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if BPTH has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Bio-Path Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BPTH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate BPTH's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BPTH's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BPTH's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BPTH's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Peter Nielsen (70yo)
Mr. Peter H. Nielsen, MBA, is a Co-Founded Bio-path Holdings, Inc. in 2007 and has been its Chairman, President, Chief Executive Officer, Chief Financial Officer and Treasurer since 2008. Mr. Nielsen licen ...
CEO Compensation Analysis
Compensation vs Market: Peter's total compensation ($USD734.73K) is about average for companies of similar size in the US market ($USD614.05K).
Compensation vs Earnings: Peter's compensation has increased whilst the company is unprofitable.
|Chairman of the Scientific Advisory Board||4.67yrs||no data||no data|
|Independent Director||0.50yr||US$40.20k||no data|
|Independent Director||2.17yrs||US$41.02k||no data|
|Member of the Scientific Advisory Board||1.25yrs||no data||no data|
|Member of the Scientific Advisory Board||1.67yrs||no data||no data|
|Independent Director||6.17yrs||US$44.02k||no data|
|Member of the Scientific Advisory Board||3.17yrs||no data||no data|
Experienced Board: BPTH's board of directors are considered experienced (3.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 345.1%.
Bio-Path Holdings, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Bio-Path Holdings, Inc.
- Ticker: BPTH
- Exchange: NasdaqCM
- Founded: 2007
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$17.315m
- Shares outstanding: 3.69m
- Website: https://www.biopathholdings.com
Number of Employees
- Bio-Path Holdings, Inc.
- 4710 Bellaire Boulevard
- Suite 210
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BPTH||NasdaqCM (Nasdaq Capital Market)||Yes||Common Stock||US||USD||Feb 2008|
|IBPB||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Feb 2008|
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia and myelodysplastic syndrome, as well as in Phase IIa clinical trials for the treatment of chronic myeloid leukemia. The company is also developing Liposomal Bcl2 for the treatment of lymphoma; and Liposomal Stat3 that is in preclinical stage for the treatment of pancreatic cancer. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/10 08:35|
|End of Day Share Price||2020/04/09 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.